Session 18: Air Pollutants and PM2.5 - Chemical Composition and Health Consequences[Symposium Program （Session）]
Lung cancer is estimated to cause approximately 1.4 million cancer cases globally each year and has been the most common cancer in the world for more than two decades. Smoking and occupational exposure are known to contribute to an increase in lung cancer cases. Particulate matter pollution consists of a mixture of tiny solid and liquid droplets suspended in the air. These pollutants are composed of a variety of components, including SOx, NOx, NH3, organic chemicals, volatile metals, soil or dust particles, and allergens such as pollen or mold spores. Scientists have long believed there is a link between lung cancer and particulate matter pollution, specifically PM2.5. The environmental and health impacts of PM2.5 are an emerging research topic that require systematic research. However, the link between lung cancer and fine particulate pollution has not yet been studied in detail by many research institutions around the world. Therefore, ICT2025 is a good platform to discuss the linkage between PM2.5 and lung cancer.
President:
NO.:1
From air to cells: The genomic impact of environmental carcinogens
NO.:2
Air pollution and chronic obstructive pulmonary disease
NO.:3
Novel analytical and bio-analytical concepts for addressing the composition as well as the toxicological impact of airborne particulate matter (PM)
NO.:4
An exposome approach to evaluate the biological and health effects of air pollution: Evidence from multiple studies
NO.:5
Study on the Mechanism of Pulmonary Injury Caused by Inhalation Exposure to Microplastics and Risk Assessment for Occupational Populations
Session 24: Towards Next Generation Probabilistic Risk Assessment Propelled by Artificial Intelligence and Quantitative Mode-of-Action Ontologies[Symposium Program （Session）]
At present, risk assessment of chemicals copes with uncertainty of models and results as well as with information gaps. Traditional deterministic risk assessment tackles this flaw by using uncertainty factors, worst-case approaches and thresholds. Acknowledging uncertainty necessitates embracing probabilities and accepting the remaining risk. Probabilistic methods are set to characterize uncertainties, which in turn may improve decision-making. Actual assessments of uncertainty can be more realistic than worst-case scenarios and may allow less conservative safety margins. Furthermore, this may facilitate the ongoing transition from traditional animal-based methods towards animal-free and human-centered new approach methodologies as part of next generation risk assessment. Probabilistic risk assessment as such is not new. However, a number of tools and methods have become available in recent years, which allow to reignite and leverage probabilistic risk assessment. This actually defines the scope of the present symposium. The first presentation foresees an introduction to probabilistic risk assessment and will showcase the prominent role of artificial intelligence. The second presentation will demonstrate how using chemoinformatics can improve probabilistic risk assessment. The third presentation will discuss the generation and use of mode-of-action ontologies as mechanistic frameworks that support animal-free human hazard identification. The fourth presentation will present artificial intelligence models for (eco)toxicity prediction using the adverse outcome pathway framework. The fifth presentation will revolve around exposure assessment, including the application of physiologically based kinetic models as means to quantify mode-of-action ontologies. The gender-balanced speaker line-up consists of delegates from the US, Europe and Asia with various backgrounds as well as with academic and industrial affiliations, therefore introducing a 3Is (international, interdisciplinary and intersectoral) dimension in this symposium in addition to its focus on 3Rs (replacement, reduction and refinement of animal experimentation)
NO.:1
Probability is the very guide of life (Cicero, 106-43 B.C.) and of toxicology (2024+)
NO.:2
From uncertainty to clarity: Using chemoinformatics to improve probabilistic risk assessment
NO.:3
Mode-of-action ontologies as the basis for setting up animal-free test batteries for hazard identification: Liver toxicity as a case study
NO.:4
Explainable artificial intelligence models for (eco)toxicity prediction using the adverse outcome pathway framework
NO.:5
Linking in vitro concentrations, internal tissue concentrations and external exposure through physiologically-based models
Session 25: Novel Strategies for Safety Assessment: A Paradigm Shift for the Future[Symposium Program （Session）]
Emerging therapeutic modalities, such as bispecific antibodies, novel peptide drugs and advanced cell and gene therapies, with high specificity to human targets, often exhibit low cross-reactivity in traditional animal species and present with various complex challenges for safety assessment. At the same time, tremendous endeavors have been made to reduce, refine and replace animal experimentation (3Rs) in light of US modernization act and European Commission’s intent to phase out animal testing. All these necessitate the development of innovative safety assessment approaches. This symposium aims to provide an overview of these advancements and their potential impact. Topics include strategies to minimize the use of non-human primates in drug development, the use of transgenic animals, alternative approaches including Weight of Evidence (WoE), and special considerations for the safety assessment strategy of emerging modalities such as peptide therapeutics.
The convergence of these approaches enhances safety assessments, reduces time and cost in drug development, and leads to safer therapeutic options. This symposium of speakers from multinational pharmaceutical companies associated with R&D-Based Pharmaceutical Association Committee (RDPAC) provides a platform for experts to discuss challenges and opportunities, shaping the future of drug safety evaluation.
President:
NO.:1
Strategies to minimize the use of non-human primates in drug development
NO.:2
Transgenic animal models for safety assessment
NO.:3
Alternative approaches for safety assessment
NO.:4
Nonclinical Safety Assessment of Peptide Therapeutics
Session 26: Next Generation Risk Assessment[Symposium Program （Session）]
Traditional toxicity testing based on animal experiments has served its purpose reasonably well. Yet, in light of ethics, ever-improving methods, conceptual challenges such as mixtures and large research initiatives such as Tox21 or PARC there is strong scientific and societal pressure for a paradigm shift. Although complexity and performance of in vitro and in silico methods have seen considerable progress, the incorporation of the respective approaches into regulatory assessments remains challenging. This is not the least because former projects often fell short to address specific regulatory needs. In order to overcome this, the “European Partnership for the Assessment of Risks from Chemicals” (PARC) as well as the ASPIS cluster have addressed various challenges associated with innovating chemical risk assessment. In this session, speakers will report on progress from these EU initiatives, but also taken into consideration the global perspective, how NAMs could be used to address complex endpoints like developmental and reproductive toxicity (DART) or in risk assessment of complex toxins like microcystins.
President:
NO.:2
Using NGRA to analyse microcystin toxicity
NO.:3
The ASPIS Safety profiler Algorithm (ASPA)
NO.:4
Improving the EST for NGRA of DART substances
NO.:5
AI-Driven text mining and NLP for advancing AOP development in chemical risk assessment: A PARC Perspective
